EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling

Hoang Dat Nguyen iD, Vinh Hoa Pham, Richard M Hoglund, Joel Tarning iD, Junjie Ding

British Journal of Clinical Pharmacology · 2026-06 · 92 (6) · 1845-1856

DOI: 10.1002/bcp.70443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 26.01.2026. Verfasst von Hoang Dat Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Master of Science Program in Biopharmaceutical Sciences, Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Linezolid, Rifampin, Models, Biological, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The study aims to develop a physiologically‐based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP‐binding cassette sub‐family B member 1 ( ABCB1 ) and ATP‐binding cassette super‐family G member 2 ( ABCG2 ) in the drug–drug interaction (DDI) between rifampin and linezolid and to predict the impact of high‐dose rifampin on linezolid pharmacokinetics (PK).

Methods

We developed a PBPK model of linezolid and verified this using published clinical PK data. The built‐in PK‐SIM PBPK model for rifampin was used as a perpetrator model, which incorporate ABCB1 and ABCG2 transporter activity, along with inhibition and induction kinetic parameters. Using the developed PBPK models, linezolid PK was predicted when co‐administered with rifampin and verified using published data. Based on the developed DDI model, linezolid exposure when co‐administered with high‐dose rifampin at steady state was predicted.

Results

The developed linezolid PBPK model had acceptable predictive performance for 36 different PK arms from 13 individual clinical studies. The PBPK‐predicted DDI effect of standard dose rifampin on linezolid, with AUC and C max ratios of 0.77 and 0.87, respectively, aligned well with observed DDI ratio. PBPK simulations indicated that both ABCG2 and ABCB1 contributed to the DDI between linezolid and rifampin, with ABCB1 playing the major role in the interaction. Increasing the daily dose of rifampin from 10 mg/kg to 20–40 mg/kg resulted in a similar linezolid exposure.

Conclusions

Our study suggested that ABCB1 is the primary transporter responsible for the interaction between rifampin and linezolid. The DDI effect of high‐dose rifampin on linezolid plasma exposure is similar to that of standard‐dose rifampin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidRifampinModels, BiologicalATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsHumansDrug InteractionsATP Binding Cassette Transporter, Subfamily BDose-Response Relationship, Drug

Stichwörter der Autor:innen

drug–drug interactionlinezolidphysiologically‐based pharmacokinetic modelrifampintransporter

Substanzen

LinezolidRifampinATP Binding Cassette Transporter, Subfamily G, Member 2ATP Binding Cassette Transporter, Subfamily BABCB1 protein, humanABCG2 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Master of Science Program in Biopharmaceutical Sciences, Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
  • Department of Pharmacology and Pharmacogenomics Research Center, Inje University, College of Medicine, Busan, Republic of Korea.
  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Infectious Diseases Data Observatory, University of Oxford, Oxford, UK.

ORCID-Profile: Hoang Dat Nguyen, Joel Tarning

Förderung

  • Wellcome Trust

Zitieren

APA

Nguyen, H. D., Pham, V. H., Hoglund, R. M., Tarning, J., & Ding, J. (2026). Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 92(6), 1845-1856. https://doi.org/10.1002/bcp.70443

Vancouver

Nguyen HD, Pham VH, Hoglund RM, Tarning J, Ding J. Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling. British Journal of Clinical Pharmacology. 2026;92(6):1845-1856. doi:10.1002/bcp.70443

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Hoang Dat and Pham, Vinh Hoa and Hoglund, Richard M and Tarning, Joel and Ding, Junjie},
  title = {Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {6},
  pages = {1845--1856},
  doi = {10.1002/bcp.70443}
}
Kostenlos starten →